Stockwatch: Pricing Delusions Of Blockbuster Proportions
Executive Summary
Sales expectations for the products of companies like Acadia, BTG, Keryx and probably Sarepta remain too high, despite the bursting of the last biotech bubble. Aggressive price increases have traditionally been one way to inch closer to those expectations but that door has closed.